Systemic Mastocytosis Clinical Trial
Official title:
Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.
The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01807598 -
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
|
Phase 2 | |
| Completed |
NCT00171912 -
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
|
Phase 2 | |
| Completed |
NCT02441166 -
Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
|
N/A | |
| Withdrawn |
NCT03739606 -
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT00979160 -
Evaluation of Response of Dasatinib to Treat Mastocytosis
|
Phase 2 | |
| Active, not recruiting |
NCT04681105 -
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT03401060 -
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
|
Phase 3 | |
| Terminated |
NCT02415608 -
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
|
Phase 2 | |
| Completed |
NCT02478957 -
Treatment of Indolent Systemic Mastocytosis With PA101
|
Phase 2 | |
| Terminated |
NCT00918931 -
Obatoclax for Systemic Mastocytosis
|
Phase 2 | |
| Completed |
NCT00493129 -
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
|
Phase 2 | |
| Completed |
NCT01297777 -
Imatinib in KIT-negative Systemic Mastocytosis
|
Phase 4 | |
| Terminated |
NCT03214666 -
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01334996 -
Use of Tamoxifen in Systemic Mastocytosis
|
||
| Completed |
NCT00449748 -
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
|
Phase 2 | |
| Completed |
NCT00109707 -
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
|
Phase 1/Phase 2 |